NinePointTwo Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

NinePointTwo Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,868	Closed	-$292K	–	340
2023 Q2	$292K	Buy	+2,868	New	+$271K	0.11%	62
2022 Q1	–	Sell	-10,799	Closed	-$284K	–	257
2021 Q4	$284K	Buy	+10,799	New	+$836K	0.09%	94

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

NinePointTwo Capital's RETA Position: Q3 2023 in Review

NinePointTwo Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,868 shares — an estimated $292K sold.

NinePointTwo Capital first reported a position in RETA in Q4 2021 and held it in 2 quarters. The position peaked at $292K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

NinePointTwo Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
NinePointTwo Capital sold 2,868 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $292K.
NinePointTwo Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 2 quarters.
NinePointTwo Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $292K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.